sign in sign up
<<
Home , BayWa, Bilfinger, HHLA, Patrizia AG, Talanx, Wacker Chemie

Süss MicroTec

Germany/ Technology Hardware & Equipment Post results note

Investment Research 13 October 2014

Accumulate Preliminary release signals SMHN being on track for FY14e from Hold U/g to ‘Accumulate’/PT EUR 5 (‘Hold/under rev.’/PT EUR 8) Share price: EUR 3.99 The facts: SMHN released preliminary sales for 3Q14 of EUR 25.5m which closing price as of 10/10/2014 Target price: EUR 5.00 compares to our model assumption of EUR 27.4m while the order intake was said from Target Price: EUR 8.00 to be EUR 29m. We consider the latter in line with our expectation of guidance mid- point of EUR 30m. Please remember that SMHN gave a – at that time disappointing - Reuters/Bloomberg SMHNn.DE/SMH GY outlook of EUR 25-35m for fresh bookings. Daily avg. no. trad. sh. 12 mth 178,544 The order backlog came to EUR 82.2m and was thus higher compared to our Daily avg. trad. vol. 12 mth (m) 694.55 Price high 12 mth (EUR) 9.15 model assumptions of EUR 80.3m due to the lower sales in the quarter and Price low 12 mth (EUR) 3.93 potentially due to fx. Abs. perf. 1 mth -26.0% Management kept the guidance unchanged for 4Q14 forecasting new bookings Abs. perf. 3 mth -53.0% amounting to EUR 30-40m. For FY14e, the should come in at EUR 135- Abs. perf. 12 mth -44.4% 145m while the EBIT should achieve a slightly positive figure. Market capitalisation (EURm) 76 Our analysis: Since SMHN has not provided earnings figures, we cannot fully assess Current N° of shares (m) 19 the quarter, however, as regards operating profits, the has done well Free float 100% recently due to a low OPEX base. The problem remains still the lack of growth and 3Q14 did not appear to help here although bookings were in line with our forecast in Key financials (EUR) 12/13 12/14e 12/15e Sales (m) 135 135 143 principle. EBITDA (m) (13) 8 9 We have revised our top line projections to be on the safe side as can be seen below. EBITDA margin nm 5.8% 6.5% EBIT (m) (19) 3 5 We have assumed a cautious view on the competitive situation in the Litho segment EBIT margin nm 2.1% 3.5% and expect now a more gradual 3D ramp in the Bonder division. At the same time, the Net Profit (adj.)(m) (3) 2 3 management should focus on OPEX discipline which leads to higher earnings in our ROCE -5.1% 2.5% 3.8% model for FY14e and FY15e while due to the lower revenue base, our EBIT estimates Net debt/(cash) (m) (36) (29) (31) Net Debt Equity -0.3 -0.3 -0.3 decline significantly as of FY16e. In conjunction with a more cautious view on working Net Debt/EBITDA 2.7 -3.7 -3.3 capital, but better financing costs our new DCF based PT comes to EUR 5 (EUR 8). Int. cover(EBITDA/Fin.int) (100.8) 75.5 241.6 EV/Sales 0.7 0.4 0.3 Estimate changes EV/EBITDA nm 6.5 5.3 in EUR m FY14 old FY14 new change FY15 old FY15 new change FY16 old FY16 new change EV/EBITDA (adj.) nm 6.5 5.3 Sales 140.0 135.0 -4% 150.0 142.5 -5% 182.0 156.0 -14% EV/EBIT nm 17.4 9.9 Rep. EBIT 1.5 2.9 93% 4.4 4.9 12% 15.5 9.5 -39% P/E (adj.) nm 42.0 23.6 EBIT margin 1.1% 2.1% 110bp 2.9% 3.5% 50bp 8.5% 6.1% -240bp P/BV 1.1 0.7 0.7 Reported net profit 0.8 1.8 127% 2.8 3.2 16% 10.4 6.4 -38% OpFCF yield 17.8% -9.4% 1.5% Rep. EPS [EUR]* 0.04 0.10 150% 0.15 0.17 13% 0.54 0.34 -37% Dividend yield 0.0% 0.0% 0.0% Sources: equinet estimates EPS (adj.) (0.15) 0.10 0.17 BVPS 5.72 5.82 5.99 Conclusion & Action: The preliminary release signals that booking-wise, SMHN is DPS 0.00 0.00 0.00 on track to achieve the guidance and also the full year targets should be met – the sales outlook probably at the lower end. Thus, the release today might not be

regarded as a major event, but the company was obviously able to regain some confidence. The current share levels of around EUR 4 are well backed by c. EUR 1.50 vvdsvdvsdy 10 net cash (equinet estimate per year end’14) and about EUR 1 per share in real estate. 9

8 Although significantly delayed – the 3D integration opportunity still exists, but the

7 respective visibility appears to be low while for the bulk of the operating business, we

6 expect SMHN to stay profitable on the group level. Consequently, from a pure

5 valuation point of view, an investment appears attractive and the strong share price 4 drop of the recent past allows us to upgrade the recommendation to ‘Accumulate’

3 Sep 13 Okt 13 Nov 13 Dez 13 Jan 14 Feb 14 Mrz 14 Apr 14 Mai 14 Jun 14 Jul 14 Aug 14 Sep 14 Okt 14 (‘Hold/under review’). We might become more positive on SMHN once we are able to

Source: Factset identify a real trigger. Please also remember that SMHN is still on the search for a SUESS MICROTEC Tec Dax (Rebased) Shareholders: new CEO which might take a while. Analyst(s): Adrian Pehl, CFA +49 69 58997 438 [email protected] For important disclosure information, please refer to the disclaimer page of this report For company description please see summary table footnote

Produced by: All ESN research is available on Bloomberg (“ESNR”), Thomson-Reuters, Capital IQ, FactSet

Distributed by the Members of ESN (see last page of this report)

Süss MicroTec

Discounted Cash Flow model Phase I Phase II Phase III EUR m 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Sales 135.0 142.5 156.0 167.0 176.6 182.8 189.2 195.8 202.7 209.7 213.9 Sales growth n/m 5.6% 9.5% 7.1% 5.7% 3.5% 3.5% 3.5% 3.5% 3.5% 2.0% EBIT 2.9 4.9 9.5 13.0 16.2 13.6 14.1 14.6 15.1 15.6 15.9 EBIT margin 2.1% 3.5% 6.1% 7.8% 9.2% 7.5% 7.5% 7.5% 7.4% 7.5% 7.5% Tax (1.0) (1.7) (3.1) (4.2) (5.0) (4.2) (4.4) (4.5) (4.7) (4.8) (4.9) Normative tax rate EBIT 35.0% 34.0% 33.0% 32.0% 31.0% 31.0% 31.0% 31.0% 31.0% 31.0% 31.0% NOPAT 1.9 3.3 6.3 8.8 11.2 9.4 9.7 10.1 10.4 10.8 11.0 Depreciation 4.9 4.3 4.1 4.1 4.2 4.2 4.3 4.5 4.6 4.7 4.8 in % of Sales 3.6% 3.0% 2.6% 2.4% 2.4% 2.3% 2.3% 2.3% 2.3% 2.3% 2.2% Capex (4.1) (4.3) (4.7) (5.0) (5.3) (5.0) (5.2) (5.4) (5.6) (5.8) (4.8) in % of Sales 3.0% 3.0% 3.0% 3.0% 3.0% 2.8% 2.8% 2.8% 2.8% 2.8% 2.3% Provision delta 0.9 0.9 0.9 0.9 0.9 0.6 0.6 0.6 0.6 0.6 0.3 in % of Sales 0.7% 0.6% 0.6% 0.5% 0.5% 0.3% 0.3% 0.3% 0.3% 0.3% 0.2% Change in working capital (10.8) (3.2) (5.7) (4.6) (4.0) (2.6) (2.7) (2.8) (2.9) (3.0) (0.4) in % of Sales -8.0% -2.2% -3.6% -2.8% -2.3% -1.4% -1.4% -1.4% -1.4% -1.4% -0.2% Other current assets delta 0.4 0.4 0.4 0.4 0.4 0.2 0.2 0.2 0.2 0.2 0.1 in % of Sales 0.3% 0.3% 0.2% 0.2% 0.2% 0.1% 0.1% 0.1% 0.1% 0.1% 0.0% Free Cash Flow -6.8 1.4 1.4 4.5 7.3 6.8 6.9 7.1 7.3 7.5 11.0 FCF growth nm nm -5.1% 230.4% 59.8% -6.9% 2.5% 2.7% 2.9% 3.0% 46.0% Present Value FCF -6.7 1.3 1.1 3.3 4.8 4.1 3.8 3.6 3.3 3.1 56.3

PV Phase I 3.9 MCap 135.5 Targ. equity ratio 91.7% PV Phase II 17.9 Risk premium 4.00% Beta 1.52 PV Phase III 56.3 Risk free rate 4.50% WACC 10.07% EV 2011e 105.4 Total present value 78.1 EV 2012e 99.6 EV/EBIT 2012e 20.17 + capital increase/share buy back 0.0 EV 2013e 106.3 EV/EBIT 2013e 11.22 + associates 0.0 - market value of minorities 0.0 Sensitivity Growth rate Phase III + cash and liquid assets 37.1 Analysis 1.0% 1.5% 2.0% 2.5% 3.0% - interest bearing debt* 17.8 9.56% 5.70 5.27 5.47 5.70 5.97 Implied Mcap 97.5 9.82% 5.49 5.09 5.28 5.49 5.73 Number of shares 19.1 WACC 10.07% 5.29 4.93 5.10 5.29 5.52 10.32% 5.11 4.77 4.93 5.11 5.31 Implied value per share 5.10 10.57% 4.94 4.63 4.77 4.94 5.13 *) including pension provisions Source: equinet

Page 2

Süss MicroTec

Süss MicroTec: Summary tables PROFIT & LOSS (EURm) 12/2011 12/2012 12/2013 12/2014e 12/2015e 12/2016e Sales 175 164 135 135 143 156 Cost of Sales & Operating Costs -149 -147 -135 -127 -133 -142 Non Recurrent Expenses/Income -1.4 1.8 -13.2 0.0 0.0 0.0 EBITDA 24.9 18.6 -13.4 7.8 9.3 13.6 EBITDA (adj.)* 26.3 16.8 -0.2 7.8 9.3 13.6 Depreciation -2.1 -2.2 -2.6 -2.6 -2.7 -2.9 EBITA 22.8 16.4 -16.0 5.2 6.5 10.7 EBITA (adj)* 24.2 14.6 -2.8 5.2 6.5 10.7 Amortisations and Write Downs 0.0 0.0 0.0 0.0 0.0 0.0 of which PPA amortisation 0.0 -0.6 -0.8 -0.8 -0.8 -0.8 EBIT 18.6 11.7 -19.4 2.9 4.9 9.5 EBIT (adj.)* 20.0 10.5 -5.4 3.7 5.7 10.3 Net Financial Interest 0.1 0.0 -0.1 -0.1 0.0 0.1 Other Financials 1.0 0.0 0.0 0.0 0.0 0.0 Associates 0.0 0.0 0.0 0.0 0.0 0.0 Other Non Recurrent Items 0.0 0.0 0.0 0.0 0.0 0.0 Earnings Before Tax (EBT) 19.6 11.8 -19.6 2.8 4.9 9.6 Tax -5.8 -4.1 3.6 -1.0 -1.7 -3.2 Tax rate 29.5% 35.2% 18.3% 35.0% 34.0% 33.0% Discontinued Operations 0.0 1.5 0.0 0.0 0.0 0.0 Minorities -0.3 0.0 0.0 0.0 0.0 0.0 Net Profit (reported) 13.5 9.1 -16.0 1.8 3.2 6.4 Net Profit (adj.) 14.5 7.3 -2.8 1.8 3.2 6.4 CASH FLOW (EURm) 12/2011 12/2012 12/2013 12/2014e 12/2015e 12/2016e Cash Flow from Operations before change in NWC 18.4 14.7 -8.3 7.7 8.6 11.5 Change in Net Working Capital -16.6 -16.0 33.6 -10.8 -3.2 -5.7 Cash Flow from Operations 1.8 -1.3 25.3 -3.1 5.4 5.8 Capex -3.6 -4.2 -3.3 -4.1 -4.3 -4.7 Net Financial Investments 0.5 -6.0 -8.5 0.0 0.0 0.0 Free Cash Flow -1.4 -11.5 13.5 -7.2 1.1 1.2 Dividends 0.0 0.0 0.0 0.0 0.0 0.0 Other (incl. Capital Increase & share buy backs) 6.5 1.6 -10.4 0.4 0.4 0.4 Change in Net Debt 5.1 -9.9 3.1 -6.8 1.5 1.5 NOPLAT 14.1 6.8 -4.4 2.4 3.8 6.9 BALANCE SHEET & OTHER ITEMS (EURm) 12/2011 12/2012 12/2013 12/2014e 12/2015e 12/2016e Net Tangible Assets 9.5 12.1 20.9 21.6 22.4 23.5 Net Intangible Assets (incl.Goodwill) 22.2 22.9 19.8 18.3 17.4 16.9 Net Financial Assets & Other 0.7 0.9 0.6 0.6 0.6 0.6 Total Fixed Assets 32.3 35.8 41.3 40.5 40.4 41.0 Inventories 71.6 82.2 71.1 60.8 64.1 70.2 Trade receivables 17.8 21.8 11.1 16.2 17.1 18.7 Other current assets 8.9 3.5 8.9 9.2 9.6 10.0 Cash (-) -57.2 -37.1 -47.5 -40.7 -42.2 -43.7 Total Current Assets 155 145 139 127 133 143 Total Assets 188 180 180 167 173 184 Shareholders Equity 120 127 109 111 114 121 Minority 0.7 0.0 0.0 0.0 0.0 0.0 Total Equity 120 127 109 111 114 121 Long term interest bearing debt 4.3 4.0 10.3 10.3 10.3 10.3 Provisions 9.3 8.1 9.8 10.8 11.8 12.8 Other long term liabilities 27.2 30.5 34.7 17.9 19.0 20.7 Total Long Term Liabilities 40.8 42.5 54.8 38.9 41.1 43.8 Short term interest bearing debt 10.1 0.3 1.2 1.2 1.2 1.2 Trade payables 7.6 6.9 5.6 6.8 7.1 7.8 Other current liabilities 8.9 3.5 8.9 9.2 9.6 10.0 Total Current Liabilities 26.6 10.7 15.6 17.2 17.9 19.0 Total Liabilities and Shareholders' Equity 188 180 180 167 173 184 Net Capital Employed 114 133 118 111 115 122 Net Working Capital 63.4 79.4 45.9 56.7 59.9 65.5 GROWTH & MARGINS 12/2011 12/2012 12/2013 12/2014e 12/2015e 12/2016e Sales growth 26.1% -6.6% -17.9% 0.4% 5.6% 9.5% EBITDA (adj.)* growth 30.3% -36.3% n.m. n.m. 18.9% 46.5% EBITA (adj.)* growth 32.7% -39.6% n.m. n.m. 26.6% 64.2% EBIT (adj)*growth 42.6% -47.2% n.m. n.m. 55.1% 79.1%

Page 3

Süss MicroTec

Süss MicroTec: Summary tables GROWTH & MARGINS 12/2011 12/2012 12/2013 12/2014e 12/2015e 12/2016e Net Profit growth 70.2% -49.7% n.m. n.m. 78.0% 98.1% EPS adj. growth 66.2% -50.2% n.m. n.m. 78.0% 98.1% DPS adj. growth EBITDA (adj)* margin 15.0% 10.2% n.m. 5.8% 6.5% 8.7% EBITA (adj)* margin 13.8% 8.9% -2.1% 3.8% 4.6% 6.9% EBIT (adj)* margin 11.4% 6.4% n.m. 2.7% 4.0% 6.6%

RATIOS 12/2011 12/2012 12/2013 12/2014e 12/2015e 12/2016e Net Debt/Equity -0.4 -0.3 -0.3 -0.3 -0.3 -0.3 Net Debt/EBITDA -1.7 -1.8 2.7 -3.7 -3.3 -2.4 Interest cover (EBITDA/Fin.interest) n.m. n.m. n.m. 75.5 n.m. n.m. Capex/D&A 57.4% 61.1% 54.3% 82.6% 98.7% 113.9% Capex/Sales 2.1% 2.6% 2.4% 3.0% 3.0% 3.0% NWC/Sales 36.1% 48.5% 34.1% 42.0% 42.0% 42.0% ROE (average) 12.8% 5.9% -2.3% 1.6% 2.9% 5.4% ROCE (adj.) 14.8% 6.0% -5.1% 2.5% 3.8% 6.5% WACC 10.1% 10.1% 10.1% 10.1% 10.1% 10.1% ROCE (adj.)/WACC 1.5 0.6 -0.5 0.2 0.4 0.6

PER SHARE DATA (EUR)*** 12/2011 12/2012 12/2013 12/2014e 12/2015e 12/2016e Average diluted number of shares 18.9 19.1 19.1 19.1 19.1 19.1 EPS (reported) 0.71 0.48 -0.84 0.10 0.17 0.34 EPS (adj.) 0.77 0.38 -0.15 0.10 0.17 0.34 BVPS 6.33 6.65 5.72 5.82 5.99 6.32 DPS 0.00 0.00 0.00 0.00 0.00 0.00

VALUATION 12/2011 12/2012 12/2013 12/2014e 12/2015e 12/2016e EV/Sales 0.4 0.8 0.7 0.4 0.3 0.3 EV/EBITDA 2.8 7.1 n.m. 6.5 5.3 3.5 EV/EBITDA (adj.)* 2.7 7.9 n.m. 6.5 5.3 3.5 EV/EBITA 3.1 8.1 -5.7 9.8 7.5 4.4 EV/EBITA (adj.)* 2.9 9.0 -32.9 9.8 7.5 4.4 EV/EBIT 3.8 11.3 n.m. 17.4 9.9 5.0 EV/EBIT (adj.)* 3.5 12.5 n.m. 13.6 8.5 4.6 P/E (adj.) 7.3 22.1 n.m. 42.0 23.6 11.9 P/BV 0.9 1.3 1.1 0.7 0.7 0.6 Total Yield Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% EV/CE 0.7 1.2 1.0 0.5 0.5 0.4 OpFCF yield -1.8% -3.4% 17.8% -9.4% 1.5% 1.5% OpFCF/EV -2.7% -4.2% 24.3% -14.2% 2.3% 2.4% Payout ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Dividend yield (gross) 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

EV AND MKT CAP (EURm) 12/2011 12/2012 12/2013 12/2014e 12/2015e 12/2016e Price** (EUR) 5.63 8.44 6.46 3.99 3.99 3.99 Outstanding number of shares for main stock 18.9 19.1 19.1 19.1 19.1 19.1 Total Market Cap 106 161 124 76 76 76 Net Debt -43 -33 -36 -29 -31 -32 o/w Cash & Marketable Securities (-) -57 -37 -47 -41 -42 -44 o/w Gross Debt (+) 14 4 11 11 11 11 Other EV components 6 4 3 3 3 4 Enterprise Value (EV adj.) 70 132 91 50 49 48 Source: Company, Equinet estimates.

Notes * Where EBITDA (adj.) or EBITA (adj)= EBITDA (or EBITA) -/+ Non Recurrent Expenses/Income and where EBIT (adj)= EBIT-/+ Non Recurrent Expenses/Income - PPA amortisation **Price (in local currency): Fiscal year end price for Historical Years and Current Price for current and forecasted years Sector: Technology Hardware & Equipment/Semiconductors Company Description: Suss MicroTec is one of the leading semiconductor equipment manufacturers. The Garching based group has concentrated especially on four markets LED, MEMS, Advanced Packaging and 3D-Integration. The equipment produced can be divided into four groups: Mask Aligners and Coaters (Litography), Substrate Bonders and Mask Cleaning Equipment. Suss manufactures its equipment in , in and in the . The respective locations are also used for marketing as well as five further Asian locations and subsidiaries in the U.K. and in France. The company employs c. 600 people.

Page 4

Süss MicroTec

Recommendations and Disclosures Coverage Analyst Target Rating Disc. Coverage Analyst Target Rating Disc. 2G ENERGY Schäf er 34.00 Buy 2/ 3/ 5 Jenopt ik van der Horst 13.50 Buy 4SC Miemiet z 3.60 Buy 7 Joyou AG Lieder 21.90 Buy 2/ 3 Aareal Bank Häßler 36.00 Accumulat e K+S AG Schäf er 31.00 Buy Adler Modemaerkte Faust 12.70 Buy 3 Kont ron Pehl 6.50 Buy Ad pepper Lieder / Pehl 1.70 Buy 2/ 3 AG Schmidt 83.00 Accumulat e adidas Faust 75.00 Buy KTG Agrar Schäf er 23.00 Buy 2/ 3/ 5 Agrarius AG Schäf er 1.25 Buy 5/ 7 KUKA Schmidt 36.00 Reduce Aixt ron Pehl 14.00 Buy 2/ 3 LANXESS Demidova 54.00 Hold Allianz Häßler 150.00 Accumulat e Leoni Schuldt 74.00 Buy Analytik Jena Demidova 14.00 Hold 7 Linde Demidova 160.00 Hold BASF Demidova 95.00 Accumulat e Logwin Rothenbacher 1.60 Buy 2/ 3 BAUER AG Schmidt 18.00 Hold Luf t hansa Rothenbacher 15.00 Buy Bayer Miemiet z 96.00 Hold MAN Schuldt 85.00 Hold BayWa Schäf er 42.00 Buy 5 MAX Aut omat ion AG Schmidt 6.00 Buy 2/ 3 BB Biot ech Miemiet z 164.00 Buy 7 Medion Faust 13.00 Hold Beiersdorf Demidova 64.00 Sell Merck Miemiet z 66.50 Hold Berent zen Faust 5.00 Hold 2/ 3 Met ro Faust 43.00 Buy SE Faust 50.00 Hold MIFA Faust Suspended Suspended 2/ 3/ 4/ 5 Biot est Miemiet z 93.00 Buy 2/ 3/ 4/ 5 MLP Häßler 5.70 Accumulat e 2/ 3 BMW Schuldt 110.00 Buy MTU Pehl 71.00 Hold 2 Celesio Lieder 23.50 Hold Re Häßler 150.00 Hold Cenit Pehl 13.50 Buy 2/ 3 Nanogat e AG Demidova 42.00 Accumulat e 2/ 3 comdirect Häßler 9.50 Accumulat e PATRIZIA AG Häßler 10.00 Hold Commerzbank Häßler 13.00 Hold Pehl 73.00 Hold Continental Schuldt 158.00 Hold Porsche Schuldt 64.00 Hold CYTOTOOLS AG MIemiet z 58.00 Accumulat e 2/ 3 Post bank Häßler 32.00 Accumulat e Daimler AG Schuldt 62.00 Reduce PSI Schäf er 13.00 Hold 2/ 3 Daldrup & Soehne Schäf er 15.00 Accumulat e 2/ 3/ 5 Puma Faust 210.00 Hold Deut sche Bank Häßler 28.00 Hold Rheinmetall Pehl 47.50 Accumulat e Deut sche Biogas Schäf er 6.00 Buy 2/ 3/ 5 Rhoen-Klinikum Lieder 25.00 Accumulat e Deut sche Boerse Häßler 50.00 Hold RIB Software Rothenbacher 17.00 Buy 2/ 3/ 4/ 5 Deut sche EuroShop Rothenbacher 36.00 Hold RWE Schäf er 25.00 Hold Deutsche Forfait Häßler 5.60 Rat ing Suspended 2/ 3/ 4/ 5 SAF-HOLLAND Schuldt 13.60 Buy 7 Deut sche Post Rothenbacher 24.00 Hold Seven Principles AG Pehl 4.50 Accumulat e 2/ 3/ 5 Deut sche Telekom Pehl 13.00 Hold SIEGFRIED HOLDING AG Miemiet z 197.00 Buy 7 Deut z AG Schmidt 5.40 Hold Singulus Technologies van der Horst 0.85 Hold 5 DMG MORI SEIKI AG Schmidt 30.00 Buy SLM Solutions Pehl 24.00 Buy 5 Douglas Holding Faust 38.00 Hold SMT SCHARF AG Schmidt 18.00 Hold 2/ 3 Draegerwerk Lieder 71.00 Reduce Suess MicroTec Pehl 5.00 Accumulat e 2/ 3 Drillisch Pehl 32.00 Accumulat e SURTECO Lieder 29.00 Hold 2/ 3 E.ON Schäf er 14.00 Hold Symrise AG Demidova 36.00 Hold Elmos Semiconduct or van der Horst 19.00 Buy SYZYGY AG Lieder / Pehl 6.60 Accumulat e 2/ 3 ElringKlinger Schuldt 24.00 Reduce Group Häßler 28.00 Accumulat e Epigenomics AG Miemiet z Suspended Buy 2/ 3/ 5 TUI Rothenbacher 16.00 Buy Euromicron AG Pehl 19.00 Buy 2/ 3 United Internet Pehl 38.00 Accumulat e Evonik Demidova 34.00 Accumulat e Uzin Ut z Lieder 27.00 Buy 2/ 3 Fielmann Lieder 47.00 Hold VBH Holding Faust 2.80 Hold 2/ 3 Fraport Rothenbacher 59.00 Buy VIB Vermoegen Rothenbacher 14.50 Hold Freenet Pehl 22.50 Accumulat e 2 Volkswagen Schuldt 235.00 Buy Fresenius Lieder 39.00 Hold Schmidt 78.00 Buy Fresenius Medical Care Lieder 58.00 Buy Demidova 71.00 Sell Fuchs Petrolub Demidova 28.00 Reduce Wilex Miemiet z 1.38 Buy 2/ 3 GEA Group Schmidt 40.00 Buy Wincor Nixdorf Pehl 43.00 Accumulat e 2 Gerresheimer AG Lieder 43.00 Hold GERRY WEBER Faust 34.00 Hold Gesco Schmidt 74.00 Hold 2/ 3 GFT Technologies Schuldt 10.20 Buy 2/ 3 Gigaset Pehl 0.90 Accumulat e 2/ 3/ 4/ 5 GRAND CITY PROPERTIES Häßler 10.80 Accumulat e Grenkeleasing AG Häßler 84.00 Accumulat e Häßler 65.00 Hold Heidelberger Druck Schmidt 3.40 Buy Henkel Demidova 82.00 Hold HHLA Rothenbacher 16.00 Reduce Hocht ief Faust 69.00 Hold Hugo Boss Faust 88.00 Reduce i:FAO AG Rothenbacher 18.00 Buy 2/ 3

Source: equinet Recommendations

Page 5

Süss MicroTec

Notice according to § 34 b (German) Securities Trading Act (“Wertpapierhandelsgesetz”)

This document is issued by Equinet Bank AG (“Equinet Bank”). It has been prepared by its authors independently of the Company, and none of Equinet Bank, the Company or its shareholders has independently verified any of the information given in this document.

Equinet Bank possesses relations to the covered as detailed in the table on the previous page. Additional information and disclosures will be made available upon request and/or can be looked up on our website http://www.Equinet Bank-ag.de

1 - Equinet Bank and/or its affiliate(s) hold(s) more than 5% of the share capital of this company calculated under computational methods required by German law.

2 - Equinet Bank acts as a designated sponsor for this company, including the provision of bid and ask offers. Therefore, we regularly possess shares of the company in our proprietary trading books. Equinet Bank receives a commission from the company for the provision of the designated sponsor services.

3 – The designated sponsor services include a contractually agreed provision of research services.

4 – Within the last twelve months, Equinet Bank was involved as a lead or co-lead manager in the public offering of securities which are/whose issuer is the subject of this report.

5 – Within the last twelve months, Equinet Bank and/or its affiliate(s) provided investment banking- and/or other consultancy services for this company and/or it’s shareholders.

6 - Equinet Bank and/or its affiliate(s) has/have other substantial financial interests in relation to this issuer.

7 – Equinet Bank has entered into an agreement with this company about the preparation of research reports and – in return - receives a compensation.

Companies of the Equinet Bank group and/or its directors, officers and employees or clients may take positions in, and may make purchases and/or sales as principal or agent in the securities or related financial instruments discussed in our reports. The Equinet Bank group may provide investment banking and other services to and/or serve as directors of the companies referred to in our reports.

In compliance with Para 5 Sec. 4 of the Ordinance on the Analysis of Financial Instruments (FinAnV) Equinet Bank has realized additional internal and organizational measures, such as specific research guidelines, to prevent or manage conflicts of interest.

Neither the company nor its employees are allowed to receive donations from third parties with a special interest in the content of the analysis.

The salary of the research analysts of Equinet Bank AG does not depend on the investment banking transactions of the company. Nevertheless, this does not rule out the payment of a bonus which depends on the overall financial performance of the bank.

Particular care is taken that the individual performance of each research analyst of Equinet Bank AG is not being assessed by a manager of another business division with similar or same interests.

To assure a highest degree of transparency Equinet Bank AG regularly provides - on a quarterly basis – a summary according to Para 5 Sec. 4 No. 3 of the Ordinance on the Analysis of Financial Instruments (FinAnV). It informs about the overall analysts recommendations and sets them in a relationship to those companies, for which Equinet Bank provided investment banking services within the last twelve months. This summary is published via our website http://www.Equinet Bank-ag.de.

Furthermore, we refer to our conflict of interest policy as well as the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV) provided in the download area of our website http://www.Equinet Bank-ag.de.

Remarks

Recommendation System Buy - The stock is expected to generate a total return of over 20% during the next 12 months time horizon. Accumulate - The stock is expected to generate a total return of 10% to 20% during the next 12 months time horizon. Hold - The stock is expected to generate a total return of 0% to 10% during the next 12 months time horizon Reduce - The stock is expected to generate a total return of 0 to -10% during the next 12 months time horizon Sell - The stock is expected to generate a total return below -10% during the next 12 months time horizon

Basis of Valuation Equinet Bank uses for valuation purposes primarily DCF-Valuations and Sum-Of-The-Parts-Valuations as well as peer group comparisons.

Share prices Share prices in this analysis are the German closing prices of the last trading day before the publication.

Sources Equinet Bank has made any effort to carefully research all information contained in the analysis. The information on which the analysis is based has been obtained from sources which we believe to be reliable such as, for example, Reuters, Bloomberg and the relevant press as well as the company which is the subject of the analysis. Only that part of the research note is made available to the issuer, who is the subject of the analysis, which is necessary to properly reconcile with the facts. Should this result in considerable changes a reference is made in the research note.

Actualizations Opinions expressed in this analysis are our current opinions as of the issuing date indicated on this document. We do not commit ourselves in advance to whether and in which intervals updates are made.

Page 6

Süss MicroTec

DISCLAIMER

THE PREPARATION OF THIS DOCUMENT IS SUBJECT TO REGULATION BY GERMAN LAW. THIS DOCUMENT IS BEING SUPPLIED TO YOU SOLELY IN YOUR CAPACITY AS A PROFESSIONAL INSTITUTIONAL INVESTOR FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. NEITHER THIS DOCUMENT NOR ANY COPY OF IT MAY BE TAKEN OR TRANSMITTED INTO , CANADA OR JAPAN OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN OR TO ANY RESIDENT THEREOF.

THE DELIVERY OF THIS RESEARCH REPORT TO U.S. PERSONS IN THE UNITED STATES OF AMERICA IS MADE BY AND UNDER THE RESPONSIBILITY OF GSN NA, INC. (REGISTERED WITH THE SEC). THIS RESEARCH REPORT IS ONLY INTENDED FOR PERSONS WHO QUALIFY AS MAJOR U.S. INSTITUTIONAL INVESTORS, AS DEFINED IN SECURITIES EXCHANGE ACT RULE 15A-6, AND DEAL WITH GSN NA, INC. HOWEVER, THE DELIVERY OF THIS RESEARCH REPORT OR SUMMARY TO ANY U.S. PERSON SHALL NOT BE DEEMED A RECOMMENDATION OF GSN NA, INC. TO EFFECT ANY TRANSACTIONS IN THE SECURITIES DISCUSSED HEREIN OR AN ENDORSEMENT OF ANYOPINION EXPRESSED HEREIN. GSN NA, INC. MAY FURNISH UPON REQUEST ALL INVESTMENT INFORMATION AVAILABLE TO IT SUPPORTING ANY RECOMMENDATIONS MADE IN THIS RESEARCH REPORT. ALL TRADES WITH U.S. RECIPIENTS OF THIS RESEARCH SHALL BE EXECUTED THROUGH GSN NA, INC.

THIS DOCUMENT IS FOR DISTRIBUTION IN THE U.K. ONLY TO PERSONS WHO HAVE PROFESSSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND FALL WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE “ORDER”) OR (ii) ARE PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, NAMELY HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS “RELEVANT PERSONS”). THIS DOCUMENT MUST NOT BE ACTED ON OR RELIED UPON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS DOCUMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

THE DISTRIBUTION OF THIS DOCUMENT IN OTHER JURISDICTIONS OR TO RESIDENTS OF OTHER JURISDICTIONS MAY ALSO BE RESTRICTED BY LAW, AND PERSONS INTO WHOSE POSSESSION THIS DOCUMENT COMES SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE, ANY SUCH RESTRICTIONS. BY ACCEPTING THIS REPORT YOU AGREE TO BE BOUND BY THE FOREGOING INSTRUCTIONS. YOU SHALL INDEMNIFY EQUINET BANK AGAINST ANY DAMAGES, CLAIMS, LOSSES, AND DETRIMENTS RESULTING FROM OR IN CONNECTION WITH THE UNAUTHORIZED USE OF THIS DOCUMENT.

This report is for informational purposes only and has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. This publication is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed and recommendations made herein may not be suitable for all investors: readers must exercise their own inde-pendent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position.

The information herein is believed by Equinet Bank to be reliable and has been obtained from sources believed to be reliable, but Equinet Bank makes no representation as to the accuracy or completeness of such information. The information given in this report is subject to change without notice; it may be incomplete or condensed and it may not contain all material information concerning the Company. Opinions expressed herein may differ or be contrary to opinions expressed by other business areas of the Equinet Bank group as a result of using different assumptions and criteria. Equinet Bank is under no obligation to update or keep the information current. Equinet Bank provides data concerning the future development of securities in the context of its usual research activity. However, if a financial instrument is denominated in a currency other than an investor’s currency, a change in exchange rates may adversely affect the price or value of, or the income derived from, the financial instrument, and such investor effectively assumes currency risk. In addition, income from an investment may fluctuate and the price or value of financial instruments de-scribed in this report, either directly or indirectly, may rise or fall. Furthermore, past performance is not necessarily indicative of future results. Neither the author nor Equinet Bank accepts any liability whatsoever for any loss howsoever arising from any use of this publication or its contents or otherwise arising in connection herewith, except as provided for under applicable regulations.

Equinet Bank shall only be liable for any damages intentionally caused or which result from any gross negligence of Equinet Bank. Further Equinet Bank shall be liable for the breach of a material obligation of Equinet Bank, however, limited to the amount of the typical foreseeable which shall in no event exceed the amount of EUR 10,000. German law shall be applicable and court of jurisdiction for all disputes shall be /Main (Germany).

Competent Supervisory Authority:

Bundesanstalt für Finanzdienstleistungsaufsicht -BaFin- (Federal Financial Supervisory Authority) Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Str. 24-28, 60439 Frankfurt am Main.

Page 7

Süss MicroTec

Recommendation history for SUESS MICROTEC

Date Recommendation Target price Price at change date 13. Okt 14 Accumulate 5.00 3.99 07. Aug 14 Hold 8.00 6.18 08. Mai 14 Buy 9.00 7.50 02. Mai 14 Hold 8.00 6.99 08. Aug 13 Buy 11.00 7.27 13. Mai 13 Buy 14.00 8.78 14. Mrz 13 Buy 10.00 8.43 14. Feb 13 Hold 10.00 8.81 24. Jan 13 Buy 11.00 9.47 07. Aug 12 Buy 13.00 9.03

Source: Factset & ESN, price data adjusted for stock splits. This chart shows Equinet Bank continuing coverage of this stock; the current analyst may or may not have covered it over the entire period. Current analyst: Adrian Pehl, CFA (since 19/11/2009)

12 11 10 9 8 7 6 5 4 3 2 Sep Okt Nov Dez Jan Feb Mrz Apr Mai Jun Jul Aug Sep Okt 13 13 13 13 14 14 14 14 14 14 14 14 14 14

Price history Target price history Buy Accumulat Hold Reduce Sell Not rated

Page 8

Süss MicroTec

ESN Recommendation System The ESN Recommendation System is Absolute. It means that each stock is rated on the basis of a total return, measured by the upside potential (including dividends and capital reimbursement) over a 12 month time horizon. The ESN spectrum of recommendations (or ratings) for each stock comprises 5 categories: Buy, Accumulate (or Add), Hold, Reduce and Sell (in short: B, A, H, R, S). Furthermore, in specific cases and for a limited period of time, the analysts are allowed to rate the stocks as Rating Suspended (RS) or Not Rated (NR), as explained below. Meaning of each recommendation or rating:

 Buy: the stock is expected to generate total return of over 20% during the next 12 months time horizon  Accumulate: the stock is expected to generate total return of 10% to 20% during the next 12 months time horizon  Hold: the stock is expected to generate total return of 0% to 10% during the next 12 months time horizon.  Reduce: the stock is expected to generate total return of 0% to -10% during the next 12 months time horizon  Sell: the stock is expected to generate total return under -10% during the next 12 months time horizon  Rating Suspended: the rating is suspended due to a capital operation (take- over bid, SPO, …) where the issuer of the document (a partner of ESN) or a related party of the issuer is or could be involved or to a change of analyst covering the stock  Not Rated: there is no rating for a company being floated (IPO) by the issuer of the document (a partner of ESN) or a related party of the issuer

Equinet Bank Ratings Breakdown

Reduce Sell 6% 2% Buy 35%

Hold 36% Accumulate 21%

History of ESN Recommendation System Since 18 October 2004, the Members of ESN are using an Absolute Recommendation System (before was a Relative Rec. System) to rate any single stock under coverage. Since 4 August 2008, the ESN Rec. System has been amended as follow.  Time horizon changed to 12 months (it was 6 months)  Recommendations Total Return Range changed as below:

TODAY

SELL REDUCE HOLD ACCUMULATE BUY -10% 0% 10% 20% BEFORE SELL REDUCE HOLD ACCUMULATE BUY -15% 0% 5% 15%

Page 9

Disclaimer: These reports have been prepared and issued by the Members of European Members of ESN (European Securities Network LLP) Securities Network LLP (‘ESN’). ESN, its Members and their affiliates (and any director, officer or employee thereof), are neither liable for the proper and complete transmission of these reports nor for any delay in their receipt. Any unauthorised use, disclosure, copying, distribution, or taking of any action in reliance on these reports is strictly prohibited. The views and expressions in the reports are expressions of opinion and are given in good faith, but are subject to Banca Akros S.p.A. Equinet Bank AG change without notice. These reports may not be reproduced in whole or in part Gräfstraße 97 or passed to third parties without permission. The information herein was Viale Eginardo, 29 20149 MILANO 60487 Frankfurt am Main obtained from various sources. ESN, its Members and their affiliates (and any Germany director, officer or employee thereof) do not guarantee their accuracy or Phone: +39 02 43 444 389 Phone:+49 69 – 58997 – 410 completeness, and neither ESN, nor its Members, nor its Members’ affiliates (nor Fax:+49 69 – 58997 – 299 any director, officer or employee thereof) shall be liable in respect of any errors or Fax: +39 02 43 444 302 omissions or for any losses or consequential losses arising from such errors or omissions. Neither the information contained in these reports nor any opinion expressed constitutes an offer, or an invitation to make an offer, to buy or sell any securities or any options, futures or other derivatives related to such securities (‘related investments’). These reports are prepared for the clients of the Members of ESN only. They do not have regard to the specific investment objectives, Bank Degroof financial situation and the particular needs of any specific person who may Investment Bank of Greece receive any of these reports. Investors should seek financial advice regarding the Rue de I’Industrie 44 32 Aigialeias Str & Paradissou, 1040 Brussels appropriateness of investing in any securities or investment strategies discussed 151 25 Maroussi, Belgium or recommended in these reports and should understand that statements Greece Phone: +32 2 287 91 16 regarding future prospects may not be realised. Investors should note that income Tel: +30 210 81 73 383 Fax: +32 2 231 09 04 from such securities, if any, may fluctuate and that each security’s price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related investment mentioned in these reports. In addition, investors in securities such as ADRs, whose value are influenced by the currency of the underlying security, effectively assume currency risk. ESN, its Members and their affiliates may submit a pre-publication draft (without mentioning neither the recommendation nor the target price/fair value) of its reports for review to the Investor Relations Department of the issuer forming the subject of the report, solely for the purpose of correcting any inadvertent material BEKA Finance Pohjola Bank plc inaccuracies. Like all members employees, analysts receive compensation that is C/ Marques de Villamagna 3 P.O.Box 308 impacted by overall firm profitability For further details about the specific risks of 28001 Madrid FI- 00013 Pohjola the company and about the valuation methods used to determine the price Spain Finland targets included in this report/note, please refer to the latest relevant published Phone: +34 91 436 7813 Phone: +358 10 252 011 research on single stock or contact the analyst named on the front of the Fax: +358 10 252 2703 report/note. Research is available through your sales representative. ESN will provide periodic updates on companies or sectors based on company-specific developments or announcements, market conditions or any other publicly available information. Unless agreed in writing with an ESN Member, this research is intended solely for internal use by the recipient. Neither this document nor any copy of it may be taken or transmitted into Australia, Canada or Japan or distributed, directly or indirectly, in Australia, Canada or Japan or to any resident thereof. This document is for distribution in the U.K. Only to persons who have Caixa-Banco de Investimento SNS Securities N.V. professional experience in matters relating to investments and fall within article Rua Barata Salgueiro, nº 33 Nieuwezijds Voorburgwal 162 19(5) of the financial services and markets act 2000 (financial promotion) order 1269-057 Lisboa P.O.Box 235 2005 (the “order”) or (ii) are persons falling within article 49(2)(a) to (d) of the Portugal 1000 AE Amsterdam order, namely high net worth companies, unincorporated associations etc (all Phone: +351 21 313 73 00 The such persons together being referred to as “relevant persons”). This document Fax: +351 21 389 68 98 Phone: +31 20 550 8500 Fax: +31 20 626 8064 must not be acted on or relied upon by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. The distribution of this document in other jurisdictions or to residents of other jurisdictions may also be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this report you agree to be bound by the foregoing instructions. You shall indemnify ESN, its Members and their affiliates (and any CM - CIC Securities director, officer or employee thereof) against any damages, claims, losses, and 6, avenue de Provence detriments resulting from or in connection with the unauthorized use of this 75441 Paris document. Cedex 09 For disclosure upon “conflicts of interest” on the companies under coverage by all France the ESN Members and on each “company recommendation history”, please visit Phone: +33 1 4596 7940 the ESN website (www.esnpartnership.eu) For additional information and Fax: +33 1 4596 7748 individual disclaimer please refer to www.esnpartnership.eu and to each ESN Member websites: www.bancaakros.it regulated by the CONSOB - Commissione Nazionale per le Società e la Borsa www.bekafinance.com regulated by CNMV - Comisión Nacional del Mercado de Valores www.caixabi.pt regulated by the CMVM - Comissão do Mercado de Valores Mobiliários www.cgdsecurities.com.br regulated by the CVM – Comissão de Valores Mobiliários www.cmcics.com regulated by the AMF - Autorité des marchés financiers www.degroof.be regulated by the FSMA - Financial Services and Markets Authority www.equinet-ag.de regulated by the BaFin - Bundesanstalt für Finanzdienstleistungsaufsicht www.ibg.gr regulated by the HCMC - Hellenic Capital Market Commission www.pohjola.com regulated by the Financial Supervision Authority www.snssecurities.nl regulated by the AFM - Autoriteit Financiële Markten

Süss MicroTec Germany Technology Hardware & Equipment